Savara Ekes up on Deal with Hercules

Savara Inc. (NASDAQ: SVRA) began the trading day with its shares slightly in the green. The company, a clinical stage biopharmaceutical firm focused on rare respiratory diseases, today announced the ...

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) A…

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
MyChesCo on MSN

Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal

LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare ...
Times Argus

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

About Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of ...
Law

Norman v. Pauls et al

The Brown Law Firm, P.C. Drew T. Bell of King & Spalding has entered an appearance for Richard J. Hawkins and other defendants in a pending shareholder derivative lawsuit against Savara Inc. and its ...
Rutland Herald

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with ...
Nasdaq

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

-- Royalties Based on Annual Net Sales of MOLBREEVI in the U.S.-- -- Funds Will Strengthen the Company’s Balance Sheet for Potential U.S. Commercialization of MOLBREEVI in Autoimmune PAP -- The ...
Insider Monkey

Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections

Savara Inc. (NASDAQ:SVRA) is one of the top long-term biotechnology stocks to buy. On October 2, Savara Inc. (NASDAQ:SVRA) announced that its partner, TrilliumBiO, will present data on the development ...
The Bakersfield Californian

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW ...
Too Old to Operate

Molgramostim Improves Lung Function in Autoimmune PAP

Inhaled molgramostim significantly improved lung gas exchange and quality of life among patients with autoimmune pulmonary alveolar proteinosis. Inhaled molgramostim significantly improved lung gas ...